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Tocilizumab, A new anti-rheumatic drug developed by Hoff-
mann–La Roche and Chugai under the trade name Actemra.
It was recently approved by the U.S. Food and Drug Admin-
istration (US FDA) on January 2010 for the treatment of mod-
erate to severe rheumatoid arthritis. It is a humanized
monoclonal antibody targeted against the interleukin-6 recep-
tor (IL-6R) causing immunosuppression and mainly used for
the treatment of rheumatoid arthritis (Haghighi and Safari,
2008). Interleukin 6 is a cytokine that has a main role in im-
mune response and is implicated in the pathogenesis of many
diseases, such as autoimmune diseases, multiple myeloma
and prostate cancer (Gabay, 2006).
Tocilizumab is the ﬁrst Interleukin-6 Receptor Inhibitor.
The molecular formula of the drug is [C6428H9976N1720-
O2018S42], CAS number: [375823-41-9] and has a molecular
mass of [145.0 kDa]. The drug is a whole antibody designed
speciﬁcally to target IL-6 receptor (Fig. 1). Tocilizumab is
administered by intravenous infusions at 8 mg/kg monthly.
It is available in preparations with strength of 20 mg/ml
(Stubenrauch et al., 2009).* Corresponding author.
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Production and hosting by ElsevierOn June 2005, Tocilizumabwas approved in Japan for Castle-
man’s disease (a rare benign tumor of B cells). Intravenous Toc-
ilizumab was proved to be effective and generally well tolerated
when administered either as monotherapy or in combination
with conventional drugs used for rheumatoid arthritis (Wang
and He, 2009). On January 2009, it was approved by the Euro-
pean Medicines Agency (EMEA) for the treatment of rheuma-
toid arthritis in combination with methotrexate. It can be used
as a single medication for patients who are unable to tolerate
methotrexate. On January 2010, it was approved by the U.S.
Food and Drug Administration (US FDA) for the treatment
of moderate to severe rheumatoid arthritis (RA). The compound
is still under review and trials by Australia’s Therapeutic Goods
Administration before licensing (Smolen and Maini, 2006).2. Pharmacokinetics
A non-compartmental Pharmacokinetic analysis model from
single and multiple dose studies showed similar Pharmacoki-
netic characteristics in rheumatoid arthritis patients compared
with other healthy volunteers (Yokota et al., 2008). The Phar-
macokinetics of Tocilizumab was characterized by nonlinear
pharmacokinetic proﬁle over the dose range tested. Clearance
(CL) was concentration-dependent. Rheumatoid arthritis pa-
tients showed mean values of 0.26 ml/h/kg for CL, 160 h for
half-life (t1/2) and 60 ml/kg for volume of distribution at the
steady state (Vss) after a 10 mg/kg dose. These values were
comparable to healthy volunteers in this dose range (Yokota
et al., 2008). It is still unknown up till now whether Toc-
ilizumab is excreted in human breast milk or not. Due to the
lack of speciﬁc hepatic metabolism, it is not expected that
the pharmacokinetics of Tocilizumab are altered in patients
with hepatic impairment.
Figure 1 Blockade of IL-6 signals by anti-IL-6 receptor antibody (MRA, Tocilizumab). h, human; IL, interleukin; sIL-6R, soluble
interleukin-6 receptor. (Cited with permission from Kishimoto (2006)).
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The inﬂuence by other drugs on the pharmacokinetics of
Tocilizumab has been addressed in many studies mainly for
methotrexate (MTX). It is known that MTX can decrease
the CL of antibodies. The pharmacokinetic data obtained
from more than one study indicated that MTX appears to have
no or little inﬂuence on the pharmacokinetics of Tocilizumab.
However, it cannot be excluded that a small interference is the
cause of the slight but not marked increase in all four trough
level (Cmin) values during the four dose intervals in the 8 mg/
kg groups with co-medication of MTX (EMEA, 2009).
The bioavailability of omeprazol (10 mg oral dose) was
about 20–30% decreased after intravenous dose administra-
tion of 8 mg/kg Tocilizumab. Since omeprazole is a substrate
(and inhibitor) of CYP2C19. this can be manifested by an inhi-
bition of the down-regulating effect of IL-6 by Tocilizumab
(EMEA, 2009).
The CL of dextromethorphan (a CYP3A4 and CYP2D6
substrate) was slightly declined while the CL of its metabolite
dextrorphan (CYP3A4 substrate) was elevated (total CL
unchanged) and is not consistent with the suggestion of a
general inhibition of Tocilizumab on the down-regulating
effect of IL-6 which appeared to affect almost all CYP
enzyme-isoforms in vitro. However, this IL-6 effect occurred
only at very high concentrations in vitro (EMEA, 2009).
Since it cannot be excluded that Tocilizumab can poten-
tially inﬂuence the CL of all co-administered drugs which are
metabolized by CYP450 enzymes in the liver, the CL of several
non-steroidal anti-inﬂammatory drugs (NSAIDs) and steroids
might be affected (Kato et al., 2008). The possible interaction
is most important for CYP450 substrates with a narrow ther-
apeutic index drugs such as; warfarin and cyclosporin.Figure 2 Feedback regulation in IL-6 signaling by SOCS. IL,
interleukin; IL-6R, interleukin-6 receptor; JAK, Janus activated
kinase; SOCS, suppressors of cytokine signaling; STAT, signal
transducer and activator of transcription. (Cited with permission
from Kishimoto (2006).)4. Pharmacodynamics
Tocilizumab showed a mechanism of action that it speciﬁcally
bind to the (interleukin-6) IL-6 binding site of both sIL-6R and
mIL-6R receptors with similar afﬁnity at the nanomolar range
(Kishimoto, 2006). It was shown that IL-6 functions as aB-cell-stimulatory factor which has a major role in the induc-
tion of antibody production and as a hepatocyte-stimulatory
factor to trigger acute phase reactions. In addition, IL-6 has
many other biological activities. IL-6 is a pleiotropic cytokine
that inﬂuences antigen-speciﬁc immune responses and inﬂam-
matory reactions (Kishimoto, 2006). It is known that IL-6 pro-
duction is regulated by a feedback regulation mechanism in
IL-6 signaling triggered by suppressors of cytokine signaling
(Fig. 2). It was suggested that the binding region of Toc-
ilizumab was within the cytokine-binding region (CBR) to
which IL-6 binds. Therefore, Tocilizumab is able to block
IL-6 from binding to both receptors and thereby blocking
the IL-6 activity (Bongartz, 2008; Mihara et al., 2005).
Tocilizumab inhibits both the IL-6 classical and trans-sig-
naling pathways by binding to mIL-6R and sIL-6R (Smolen
et al., 2008). Tocilizumab binding to the receptor prevents
the receptor from binding to IL-6. The Tocilizumab-receptor
Tocilizumab: A new anti-rheumatic drug 259complex formed cannot be bioactive since it is unable to affect
the dimerization of the gp130 molecule. The IL-6 signal is
completely blocked when the dimerization step is absent
(Lipsky, 2006).
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